ADMA Biologics, Inc.
Financials
Valuation Metrics
ADMA Biologics, Inc.'s Market Cap is $2.48B. At end of 2025 it was $4.34B. Ranked #1808 of 3,118 in US market (top 58%), #649 of 1,474 on NASDAQ (top 44%), #111 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 42%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $2.48B | US#1,808/3,118 Sec#111/265 |
| Revenue | $512M | US#2,214/3,118 Sec#75/265 |
| Net Income | $169M | US#1,369/3,118 Sec#47/265 |
| Total Assets | $684M | US#2,635/3,118 Sec#134/265 |
| Net Assets | $408M | US#2,350/3,118 Sec#131/265 |
| Employees | 640 | US#2,157/3,118 Sec#72/265 |
| Value | ||
| P/E | 14.66x | US#787/3,118 Sec#24/265 |
| P/B | 6.07x | US#2,381/3,118 Sec#160/265 |
| P/S | 4.84x | US#2,310/3,118 Sec#81/265 |
| EV/EBITDA | 10.84x | US#997/3,118 Sec#32/265 |
| FCF Yield | 4.70% | US#1,472/3,118 Sec#43/265 |
| Profitability | ||
| ROE | 41.39% | US#163/3,118 Sec#13/265 |
| ROA | 24.69% | US#61/3,118 Sec#12/265 |
| Op. Margin | 42.26% | US#232/3,118 Sec#14/265 |
| Revenue Growth | 8.04% | US#1,440/3,118 Sec#104/265 |
| Earnings Growth | -19.13% | US#1,532/3,118 Sec#37/265 |
| Financial Health | ||
| Debt Ratio | 67.61% | US#741/3,118 Sec#147/265 |
| Total Debt | $204M | US#2,230/3,118 Sec#94/265 |
| FCF | $116M | US#1,663/3,118 Sec#60/265 |
| Cash | $136M | US#2,016/3,118 Sec#142/265 |
| Current Ratio | 6.97x | US#351/3,118 Sec#109/265 |
| Net Debt/EBITDA | 0.29x | US#708/3,118 Sec#37/265 |
| Performance | ||
| 1Y Return | -28.55% | US#2,507/3,118 Sec#199/265 |
| 1M Return | 13.79% | US#504/3,118 Sec#34/265 |
| From 52W High | -45.94% | US#2,479/3,118 Sec#180/265 |
| 1Y MDD | -62.71% | US#2,792/3,118 Sec#214/265 |
| Trading | ||
| Volume | 2,418,233 shares | US#985/3,118 Sec#90/265 |
| Trading Value | $27M | US#1,829/3,118 Sec#135/265 |
| Per Share | ||
| EPS | $0.75 | US#1,757/3,118 Sec#55/265 |
| BPS | $1.82 | US#2,583/3,118 Sec#180/265 |
Company Info
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.